Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 264

1.

Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes.

Buccisano F, Maurillo L, Tamburini A, Del Poeta G, Del Principe MI, Ammatuna E, Consalvo MI, Campagna S, Ottaviani L, Sarlo C, Renzi D, Faccia S, Fraboni D, Lo Coco F, Amadori S, Venditti A.

Eur J Haematol. 2008 Feb;80(2):107-14. Epub 2007 Nov 17.

PMID:
18028430
2.

Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia.

Monreal MB, Pardo ML, Pavlovsky MA, Fernandez I, Corrado CS, Giere I, Sapia S, Pavlovsky S.

Cytometry B Clin Cytom. 2006 Mar;70(2):63-70.

3.

The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS.

Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A.

Blood. 2000 Dec 1;96(12):3932-8.

PMID:
11090080
4.
5.

[Study on the Characteristics of cell cycle and proliferation of CD34+ hematopoietic stem cells in myelodysplastic syndromes].

Shi J, Shao ZH, Liu H, Jia HR, Sun J, Bai J, Wu YH, Jing LP, He GS, Cao YR, Wang XL, Tu MF, Hao YS, Yang TY.

Zhonghua Xue Ye Xue Za Zhi. 2004 Nov;25(11):641-4. Chinese.

PMID:
15634564
6.

Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.

Cilloni D, Gottardi E, Messa F, Fava M, Scaravaglio P, Bertini M, Girotto M, Marinone C, Ferrero D, Gallamini A, Levis A, Saglio G; Piedmont Study Group on Myleodysplastic Syndromes.

J Clin Oncol. 2003 May 15;21(10):1988-95.

PMID:
12743153
7.

L-selectin expression is low on CD34+ cells from patients with chronic myeloid leukemia and interferon-a up-regulates this expression.

Martín-Henao GA, Quiroga R, Sureda A, González JR, Moreno V, García J.

Haematologica. 2000 Feb;85(2):139-46.

8.

Differential gene expression of bone marrow CD34+ cells in early and advanced myelodysplastic syndrome.

Vasikova A, Budinska E, Belickova M, Cermak J, Bruchova H.

Neoplasma. 2009;56(4):335-42.

PMID:
19469654
9.

CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.

Suárez L, Vidriales MB, García-Laraña J, Sanz G, Moreno MJ, López A, Barrena S, Martínez R, Tormo M, Palomera L, Lavilla E, López-Berges MC, de Santiago M, de Equiza ME, Miguel JF, Orfao A.

Clin Cancer Res. 2004 Nov 15;10(22):7599-606.

10.

Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis.

Qi H, Xiao L, Lingyun W, Ying T, Yi-Zhi L, Shao-Xu Y, Quan P.

Ann Hematol. 2006 Feb;85(2):95-101. Epub 2005 Nov 23.

PMID:
16328478
11.
12.

Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?

Veltroni M, Sainati L, Zecca M, Fenu S, Tridello G, Testi AM, Merlone AD, Buldini B, Leszl A, Lo Nigro L, Longoni D, Bernini G, Basso G; AIEOP-MDS Study Group.

Pediatr Blood Cancer. 2009 Mar;52(3):357-63. doi: 10.1002/pbc.21874.

PMID:
19061215
13.

Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.

Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, Passamonti F, Invernizzi R, Castello A, Magrini U, Lazzarino M, Cazzola M.

J Clin Oncol. 2009 Feb 10;27(5):754-62. doi: 10.1200/JCO.2008.18.2246. Epub 2008 Dec 22.

PMID:
19103730
14.

Telomerase activity in myelodysplastic syndromes.

Gürkan E, Tanriverdi K, Başlamişli F.

Leuk Res. 2005 Oct;29(10):1131-9. Epub 2005 Apr 7.

PMID:
16111531
15.

[Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].

Li LJ, Fu R, Wang HQ, Yue LZ, Liu H, Wang J, Wang HL, Ruan EB, Qu W, Liang Y, Wang GJ, Wang XM, Liu H, Song J, Wu YH, Xing LM, Guan J, Shao ZH.

Zhonghua Yi Xue Za Zhi. 2010 Mar 16;90(10):672-7. Chinese.

PMID:
20450725
16.

CD34+ cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome.

Heinrichs S, Berman JN, Ortiz TM, Kornblau SM, Neuberg DS, Estey EH, Look AT.

Br J Haematol. 2005 Jul;130(1):83-6.

PMID:
15982348
17.

Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes.

Gianelli U, Fracchiolla NS, Cortelezzi A, Pellegrini C, Savi F, Moro A, Grimoldi MG, Deliliers GL, Coggi G, Bosari S.

Ann Hematol. 2007 Mar;86(3):185-9. Epub 2006 Nov 24.

PMID:
17124585
18.

Evaluation of CD7 and terminal deoxynucleotidyl transferase (TdT) expression in CD34+ myeloblasts from patients with myelodysplastic syndrome.

Font P, Subirá D, Mtnez-Chamorro C, Castañón S, Arranz E, Ramiro S, Gil-Fernández JJ, López-Pascual J, Alonso A, Pérez-Sáenz MA, Alaez C, Renedo M, Blas C, Escudero A, Fdez-Rañada JM.

Leuk Res. 2006 Aug;30(8):957-63. Epub 2006 Jan 18.

PMID:
16417922
19.

Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow.

Hofmann WK, de Vos S, Komor M, Hoelzer D, Wachsman W, Koeffler HP.

Blood. 2002 Nov 15;100(10):3553-60.

PMID:
12411319
20.

Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients.

Matarraz S, López A, Barrena S, Fernandez C, Jensen E, Flores-Montero J, Rasillo A, Sayagues JM, Sánchez ML, Bárcena P, Hernandez-Rivas JM, Salvador C, Fernandez-Mosteirín N, Giralt M, Perdiguer L, Laranjeira P, Paiva A, Orfao A.

Cytometry B Clin Cytom. 2010 May;78(3):154-68. doi: 10.1002/cyto.b.20513.

Supplemental Content

Support Center